Back to Japanese market after pandemic

👉 How is the Asian Market recovering after pandemic season?

"The Asian market went through very difficult period as well as Europe and US during pandemic, as a matter of fact the impossibility to move people and partially goods was forcing the Japaneese and the other major Asian countries to look back to internal production with the need to re-focus on standards and quality. Up to now there are still difficulties to recover the level of relationship of pre-pandemic and this is definitely impacting new supplier evaluation, allocation of projects to Europe and travels outside Asia and Japan to Audit new potential partners."

👉 How to recover the presence into the Japanese market which is among the top three markets for pharma?

"The reopening of the borders of last year and the presence to the CPHI of many European players coming back to this market in 2024 after quite a long time of absence it is a clear sign of the interest the European and Italian suppliers/CDMO partners still strongly maintains towards this market and the entire Asian area. In our opinion the presence in person to this event is very important in order to reinforce the knowledge the Asian Pharmaceutical companies have about the potentiality, the availability and the highest quality standard provided by the European/Italian CDMO/API Manufacturers."

👉 In which way Europe can face the competition from Asian local manufacturers?

"The Asian market is a composite field made of multiple level demands in terms of pricing, volumes, quality. Many pharmaceuticals companies in the area have targets outside Asia or within Asia in specific niche market shares based in example on sales of finished dosage forms back to Europe or USA or supplies of High standard FDF already requested within the same Asian countries by high level final users looking for Western quality and safety standards and ready to pay for it.
In both cases a “western” supplier is strongly needed in terms of safety of supply, reliability of Regulatory support, knowledge of the authorities standards in Eu and US and this will definitely represents an area where the European/Italian suppliers can play an important role based on their long lasting and successful track of records with the authorities and well established experience in both development an manufacturing of Active pharmaceuticals products and regulated intermediates."

GIOVANNI DE FILIPPPO

Sales & BD Head

Angelini Pharma | Fine Chemicals Business Unit